FDA insists on more women in drug trials

D Josefson, Josefson D
BMJ (Clinical research ed.) · 1997 · vol. 315(7112) , pp. 833 · doi:10.1136/bmj.315.7112.831f · PMID:9353497 · PMC2127578
Other OA: closed
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-16 ⓘ

The FDA mandates increased female participation in drug trials to address historical underrepresentation, though the provided text does not specify a direct connection to endometriosis or adenomyosis research.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Clinical Trials as Topic United States Food and Drug Administration Clinical Trials as Topic Drug Evaluation Female Humans United States United States Food and Drug Administration

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-08T09:52:27.483963+00:00
pubmed
last seen: 2026-10-08T22:00:28.864438+00:00
unpaywall
last seen: 2026-11-14T06:25:03.947826+00:00